$31.55
1.08% today
Nasdaq, Aug 12, 04:20 pm CET
ISIN
US45258D1054
Symbol
IMCR

Immunocore Holdings plc - ADR Stock price

$31.89
-3.13 8.94% 1M
+3.69 13.07% 6M
+2.39 8.10% YTD
-5.74 15.25% 1Y
-20.67 39.33% 3Y
+5.89 22.65% 5Y
+5.89 22.65% 10Y
+5.89 22.65% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.08 0.25%
ISIN
US45258D1054
Symbol
IMCR
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.1b
Net debt
positive
Cash
$882.8m
Shares outstanding
50.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.1
EV/Sales
3.1 | 2.8
EV/FCF
39.4
P/B
4.2
Financial Health
Equity Ratio
35.7%
Return on Equity
-14.2%
ROCE
-5.1%
ROIC
-24.1%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$356.2m | $395.3m
EBITDA
$-42.6m | $-60.3m
EBIT
$-46.4m | $-48.4m
Net Income
$-20.3m | $-41.3m
Free Cash Flow
$28.5m
Growth (TTM | estimate)
Revenue
-22.7% | 27.4%
EBITDA
57.2% | 8.9%
EBIT
54.9% | 31.3%
Net Income
77.2% | 19.1%
Free Cash Flow
128.0%
Margin (TTM | estimate)
Gross
99.3%
EBITDA
-12.0% | -15.3%
EBIT
-13.0%
Net
-5.7% | -10.5%
Free Cash Flow
8.0%
More
EPS
$-0.4
FCF per Share
$0.6
Short interest
23.2%
Employees
493
Rev per Employee
$630.0k
Show more

Is Immunocore Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Immunocore Holdings plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Immunocore Holdings plc - ADR forecast:

19x Buy
79%
4x Hold
17%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Immunocore Holdings plc - ADR forecast:

Buy
79%
Hold
17%
Sell
4%

Financial data from Immunocore Holdings plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
356 356
23% 23%
100%
- Direct Costs 2.65 2.65
19% 19%
1%
354 354
23% 23%
99%
- Selling and Administrative Expenses 161 161
35% 35%
45%
- Research and Development Expense 239 239
23% 23%
67%
-43 -43
57% 57%
-12%
- Depreciation and Amortization 3.84 3.84
10% 10%
1%
EBIT (Operating Income) EBIT -46 -46
55% 55%
-13%
Net Profit -20 -20
77% 77%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Immunocore Holdings plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunocore Holdings plc - ADR Stock News

Neutral
Seeking Alpha
3 days ago
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robertson - Head of Investor Relations David Berman - Executive Vice President of Research Development Mohammed M. Dar - Senior VP of Clinical Development & Chief Medical Officer Ralph Torbay - Corporate...
Positive
The Motley Fool
5 days ago
Immunocore Plc (IMCR 0.06%), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increase, with $98.0 million (GAAP) surpassing consensus estimates of $92.15 million.
Neutral
GlobeNewsWire
5 days ago
KIMMTRAK ® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year
More Immunocore Holdings plc - ADR News

Company Profile

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Bahija Jallal
Employees 493
Founded 2021
Website www.immunocore.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today